Short stature and gonad failure can be a side effect of total body irradiation (TBI). The purpose of the study was to evaluate the factors influencing final height and gonad function after TBI. Fifty young adults given TBI during childhood were included. Twenty-seven had been treated with growth hormone (GH). Those given single 10 Grays (Gy) or fractionated 12 Gy TBI had similar characteristics, GH peaks, final heights and gonad function. After the end of GH treatment, 11/20 patients evaluated had GH peak 410 lg/l. Final height was oÀ2 s.d. in 29 (58%). The height loss between TBI and final height (2.471.1 s.d.) was greater in those who were younger when irradiated (Po0.0001). When the GH-treated and -untreated patients were analyzed separately, this loss was correlated with the age at TBI at 4-8 years for the GHtreated and at 6-8 years for the untreated. Boys showed negative correlations between testicular volume and plasma follicle-stimulating hormone (FSH, P ¼ 0.0008) and between plasma FSH and inhibin B (P ¼ 0.005) concentrations. We concluded that the indications for GH treatment should be mainly based on the age at irradiation, taking into account the GH peak. The plasma FSH and inhibin B concentrations may predict sperm function.
Introduction
Short stature and gonad failure can be a severe side effect of the conditioning protocol used before hematopoietic cell transplantation (HCT). The final height after HCT is not reduced in patients given chemotherapy alone, 1,2 but it is in those also given body irradiation. The mean height loss between irradiation and final height is around 1 s.d., [3] [4] [5] but it can be much greater. This loss is greater in boys than in girls, 2 in those who were younger when irradiated, 2,3,6 who had previously undergone cranial irradiation 3 or were given single dose rather than fractionated total body irradiation (TBI). 2 The European BMT group reported that 140 of 181 patients given HCT and conditioned with various protocols reached final heights within 72 s.d. of the general population, and that the type of transplantation, graft-versus-host disease, growth hormone (GH) or steroid treatment did not influence final height. 2 Bakker et al. 7 also reported that male gender and a young age at the time of HCT were the only factors with an independent negative effect on longitudinal growth, whereas TBI dose (5-12 Grays (Gy)), age at the onset of puberty and the need to induce puberty did not influence growth.
The TBI may cause short stature in two ways: hypothalamic-pituitary irradiation may decrease the GH secretion; body irradiation may cause bone lesions. 8 We have evaluated the factors influencing final height and gonad function in young adults given TBI during childhood.
Patients and methods

Patients
Fifty consecutive patients (32 boys) followed by one of us (R Brauner) after TBI conditioning for HCT were included. The criteria of exclusion were factors other than conditioning for HCT that might have interfered with their growth and gonad function: the initial disease, central nervous system involvement, additional irradiation, long-term corticosteroid therapy or chronic complications of HCT. All were given HCT before their 11th year (girls) or 13th year (boys), were evaluated for their GH secretion and had reached their final height (o1 cm growth during the preceding year and a bone age 415 years in girls and 16 years in boys). The conditioning protocol for HCT included chemotherapy 9 and TBI (10 Gy single dose) with an 18 mV linear accelerator at 4.2 cGy/min (n ¼ 20) or 12 Gy (six fractions of 2 Gy within 3 consecutive days) with a 5.5 mV linear accelerator at 50 cGy/min (n ¼ 30).
Their ages were 7.273.1 years at TBI, 9.673.0 years at first endocrine evaluation and 1772.5 years at last evaluation.
Protocol
All parents gave written informed consent to the evaluations and treatment. The first evaluation was performed on fasting patients in a single morning, and included determination of height, weight, pubertal stage, plasma insulin-like growth factor (IGF) I (n ¼ 43), thyroid-stimulating hormone, free thyroxin and cortisol (at 08.00 h) concentrations. The 28 patients with high thyroid-stimulating hormone concentrations were given thyroxin (50-100 mg/m 2 /day). Plasma cortisol concentrations were normal in all patients.
The GH secretion was evaluated by stimulation testonce in all patients, twice in 45 patients, three times in 28, four times in seven and five times in two patients. The tests were repeated because of a persistent decreased growth rate despite a normal GH peak. Priming with sex steroids (testosterone heptylate 100 mg intramuscular (i.m.) every 15 days, twice in two boys or oral estradiol 0.4 mg for 10 days including the day of the test in one girl) were performed to exclude transient prepubertal GH deficiency. 10 The spontaneous secretion during sleep of 13 patients was also evaluated. Some patients also underwent a GH stimulation test (n ¼ 23) and plasma IGF I evaluation (n ¼ 22) after the end of their growth. The criteria for GH therapy were a GH peak o10 mg/l after at least one stimulation test, which is the legal limit for the reimbursement for GH treatment in France, and a total height loss from HCT X1 s.d. The decision to evaluate GH secretion and to treat with GH was taken at least 2 years after the BMT, in patients in remission and free of complications and was mainly based on the height loss from TBI and on the actual height. The bone age delay was not included in the criteria of decision. GH (0.23 mg/kg/week) was given subcutaneously on 6 days each week to 27 patients.
The basal plasma concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (in girls) and testosterone and inhibin B (in 18 boys) were measured at 412 years in girls and 414 years in boys. Normal basal plasma testosterone concentrations in adult boys are 3.5-8.5 mg/l. Normal gonad function was defined by the occurrence of spontaneous pubertal development, and regular menstruations in girls, and normal plasma FSH (o9 IU/l) and LH (o5 IU/l) concentrations. Increased plasma FSH and/or LH concentrations indicated gonad failure, which is partial when pubertal development is spontaneous and plasma sex steroids normal, and complete when pubertal development is partial or absent and plasma sex steroids low. In boys, tubular failure is defined by little or no increase in testicular volume at pubertal age and increased plasma FSH concentration. Leydig cell failure is defined by an increased plasma LH concentration with normal (partial failure) or a low (complete failure) plasma testosterone concentration. Patients of pubertal age who had an uncompensated sex steroid deficiency were given oral ethinyl estradiol (2 mg/day) at the age of around 12 years for 12 girls or testosterone heptylate (25 mg i.m. every 14 days) at the age of around 13 years for two boys during their growing period. The doses were increased to adult levels at the end of this period and the girls were also given cyclical progestin.
Methods
Height and body mass index (BMI, weight in kg/height in meters squared) data are expressed as s.d. 11, 12 and testicular volume as milliliter calculated from clinically measured testicular dimensions. 13 The pubertal growth was the increase in height between the clinical onset of puberty and the final height. Target height was calculated from parental heights.
14 GH secretion was first stimulated by a sequential arginine insulin test, and then by an ornithine or glucagon test. Aliquots of plasma were frozen at À201C to measure inhibin B concentrations by radioimmunoassay. 15 Data are means7s.d. Changes in height and BMI were analyzed by the Wilcoxon signed rank test, and the difference between groups by a Kruskall-Wallis test followed by Mann-Whitney tests. Correlations were made with a Spearman rank test.
The influence of the age at TBI, presence or absence of GH treatment and increase in weight during puberty (kg) on the height loss from TBI (difference between the height at TBI and the final height, s.d.) was analyzed using combinatorial regression, a new technique based on the Logical Analysis of Data methodology. 16 Its purpose is to construct a predictor built on Boolean conditions on variables, thus outlining the relevant thresholds at which the behavior of a variable changes.
Results
The patients given single 10 Gy or fractionated 12 Gy TBI had similar characteristics, GH peaks, final heights (Table 1 ) and gonad function (percentages of increased plasma concentrations of LH and FSH, testicular volume and plasma concentrations of testosterone and inhibin B in boys). They were therefore analyzed together.
GH secretion and IGF I
The GH peaks at the 1st, 2nd, 3rd, 4th and 5th evaluations and the corresponding plasma IGF I concentrations showed no correlation between them and each other, or with the height loss after TBI. We have therefore described the evolution in each patient (Figures 1 and 2) . The priming increased the GH peak and plasma IGF I concentration in the girl, but not in the two boys. The GH peak during sleep was 410 mg/l in 8/13 patients evaluated and was also not correlated with IGF I. After the end of GH treatment and growth, 11/20 patients evaluated had a GH peak 410 mg/l and three had peaks of 9-10 mg/l. The concomitant plasma IGF I concentrations were 4À2 zs in 14/17 patients. In the
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A-C Couto-Silva et al 13 boys evaluated twice, these concentrations increased from À2.571.4 before to À0.371.5 zs more than 1 month after the end of GH treatment (P ¼ 0.006).
Growth
The final height was o-2 s.d. in 29 (58%) patients and was not correlated with the target height.
In the 27 treated with GH, the ages were 8.573.1 years at the onset and 1572.8 years at the end of the treatment; the height decreased from -1.271.1 to -2.371.3 s.d. The patients treated with GH were compared to the untreated patients ( Table 2 ). The treated boys had characteristics similar to those of the untreated, while the treated girls were younger at TBI and had lower final height and greater height loss from TBI and difference between final height and target height than the untreated girls. Figure 1 Evolution of individual GH peaks after stimulation tests after TBI; patients classified according to their age (increasing) at TBI in each subgroup.
Triangles indicate priming. 
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The height loss between TBI and final height (2.471.1 s.d.) was greater in those who were younger when irradiated (r ¼ 0.66, Po0.0001). In the population taken as the whole, the age at TBI did not influence the height loss between 2 and 6 years or after 8 years, while it correlated with it between 6 and 8 years (Figure 3) . When the GH-treated and -untreated patients were analyzed separately, this loss correlated with the age at TBI at 4-8 years for the GH treated and at 6-8 years for the untreated. Final height and gonads after TBI A-C Couto-Silva et al
Gonad function
Only four boys had normal basal plasma concentrations of FSH and LH, suggesting normal testicular function. The 28 others had tubular failure. Nineteen had Leydig cell failure, complete in two of them. There were negative correlations between the testicular volume and plasma concentrations of FSH (P ¼ 0.0008) and between this concentration and that of inhibin B (P ¼ 0.005), but not between the testicular volume and plasma concentrations of inhibin B or between the plasma concentrations of LH and testosterone. Only two girls had normal ovarian function, four had partial ovarian failure, and 12 had complete ovarian failure. There was a positive correlation between the concentrations of FSH and LH (Rho ¼ 0.72, Po0.005).
Discussion
The diagnosis of GH deficiency and the indications for GH treatment after TBI are particularly difficult. The bone lesions may be responsible for the decreased growth rate, resistance to IGF I and poor growth response to GH therapy. 9 The following data suggest that 10 or 12 Gy of TBI does not cause permanent GH deficiency: the GH peaks of each individual patient varied greatly; these variations are similar to those observed in idiopathic short stature, but are unexpected in GH deficiency owing to cranial irradiation; the GH peaks were normal in the majority of cases during sleep and after the end of growth, as reported in nine patients; 4 and the plasma IGF I concentrations also varied and were not correlated with the GH secretion. We tried to approach the effect of the age and puberty at evaluation on the GH secretion by analyzing the succession of tests in each patient, including on priming, and by using different acronyms (younger to older) for patients in each subgroup. Brennan and Shalet 17 suggested that it is impossible to predict the gain in stature in GH deficiency owing to TBI without randomized controlled studies running through to final height.
We find that the age at TBI is the major determinant of height loss. Flechter et al.
8 studied patients given 12-14.4 Gy TBI, and found that those aged less than 8 years had more severe skeletal abnormalities than those aged 12-19 years. We find a height loss between TBI and final height greater than 2 s.d. in 13/17 boys and 10/10 girls who underwent TBI before they were 8 years old. This loss was correlated with age at TBI of 6-8 years in the whole population, at 4-8 years in the GH-treated patients and at 6-8 years in the GH-untreated patients. This suggests that the TBI performed before 4 years induces skeletal lesions responsible for major height loss, despite the GH treatment. The reduction in the loss by GH treatment is not evaluable in our patients given TBI before 4 years as all were treated with GH because they had a low GH peak. When the TBI is performed between 4 and 8 years, the height loss seems to be reduced by the GH treatment. This is concordant with the data reported by Sanders et al.:
18 the GH treatment was associated with a significantly improved final height in children younger than 10 years at HCT, but it did not influence the growth of older children.
Because idiopathic short stature is associated with low BMI, 19, 20 we evaluated the BMI and plasma leptin concentrations after TBI. 21 Taskinen and Saarinen-Pihkala 22 showed that the nutritional status before TBI, evaluated by muscle index, mid-arm circumference and serum transferin concentration, was positively correlated with the growth rate during the first year after TBI. We compared the increases in centimeters to increases in kilograms during pubertal growth and found a positive correlation. We find no effect of gender or of the type of TBI. This is at variance with reported data, probably because the doses of TBI varied, 2 whereas the patients included in the present study form a homogeneous cohort.
Few data are available on the factors influencing gonad function in adults given TBI during childhood. Petersen et al. 23 found that all the 25 adults studied had undetectable concentrations (o20 pg/ml) of inhibin B 2-12 months after testicular irradiation (2 Gy, 7-10 times). We find higher concentrations of inhibin B (10-78 pg/ml), perhaps because our patients were younger and were given lower doses of irradiation. Plasma inhibin B concentration is an additional indicator of tubular function. Sanders et al. 24 found that 13% of the 114 prepubertal boys at HCT developed normal gonad function, which is similar to our findings, that the partners of two of them became pregnant and that the large majority of those who recovered testicular function had been given cyclophosphamide, without irradiation. Among the 82 prepubertal girls who underwent HCT and were Curves are moving averages, that is: for a given age, the height loss value is computed as the average of five observations (one at the given age, the two closest younger observations and the two closest older observations).
Final height and gonads after TBI A-C Couto-Silva et al aged over 12 years at evaluation, all the five pregnancies after TBI ended in spontaneous abortion. 24 The fibrosis and alterations in the vascularization of the myometrium are additional causes of infertility. 25 The girls given TBI and having spontaneous cycles had smaller median ovary volumes and lower median total follicle numbers evaluated by echography and higher plasma FSH concentrations than those given other treatment for childhood cancer. 26 
Conclusion
This study suggests that the indications for GH treatment should be mainly based on the age at irradiation, taking into account the GH peak. GH treatment should be considered for patients given TBI before 8 years, even if the GH peak is normal. Those older at TBI with a dramatic decrease in their growth rate plus a low GH peak should be given GH; randomized controlled studies of GH treatment may help to progress in this population.
